Hematology - Lectures

Innate and adaptive immunity regulated within the tumor microenvironment

Microenvironment

Patient Selection Markers for Anti-angiogenic Agents in Metastatic Renal Cell Carcinoma: Dream or Reality?

Proffered Paper Session

Use of vena cava filters in cancer patients in California

Prevention and treatment of thrombosis

Overview of thrombosis and cancer survival

Prevention and treatment of thrombosis

Treatment of established thrombotic events

Prevention and treatment of thrombosis

Thromboprophylaxis in the non-surgical cancer patient

Prevention and treatment of thrombosis

Thromboprophylaxis in the surgical cancer patient

Prevention and treatment of thrombosis

Cellular origin and procoagulant activity of tissue factor-exposing microparticles in cancer patients

Platelets and vascular endothelium

On the use of anti-platelet drugs to diminish both tumor growth and thrombosis

Platelets and vascular endothelium

Microparticles in tumor progression

Platelets and vascular endothelium

Novel functions of tissue factor in thrombosis and in cancer

Platelets and vascular endothelium

Endothelial cell activation markers in cancer

Platelets and vascular endothelium

The role of thrombomodulin in tumor growth and metastasis

Platelets and vascular endothelium

New antithrombotic agents in the treatment of VTE; a subgroup analysis of the Phase III randomized clinical trials

Anticoagulants and cancer

The effect of aspirin on cancer mortality

Anticoagulants and cancer

LMWH and survival in lung cancer

Anticoagulants and cancer

Measurement of new oral anticoagulants

Anticoagulants and cancer

Guidelines for antithrombotics in cancer patients

Anticoagulants and cancer

New and old anticoagulants in cancer

Anticoagulants and cancer

New potential markers of severe thrombo-hemorrhagic syndrome (THS) in acute promyelocytic leukemia (APL) patients: activated FVII-antithrombin complex (FVIIa-AT) and Tissue Factor (TF) mRNA

Hematological disorders